Predicting breast cancer treatment outcome

A method to determine the survival outcome of a breast cancer afflicted subject if treated with tamoxifen or other antiestrogen agent against breast cancer, said method comprising assaying a sample of breast cancer cells from said subject for the expression level(s) of one or more genes in Table 2 or 3.

A method of determining prognosis of a subject having breast cancer if treated with tamoxifen or another antiestrogen agent against breast cancer, or of a subject afflicted with breast cancer and treated with tamoxifen or another antiestrogen agent against breast cancer, said method comprising:

• assaying for the expression level(s) of one or more genes in Table 2 or 3 from a breast cancer cell sample from said subject.

A method to determine therapeutic treatment for a breast cancer patient based upon said patient's expected response or lack of response to treatment with tamoxifen or another antiestrogen agent against breast cancer, said method comprising

• determining an expected response or non-response to treatment with tamoxifen or another antiestrogen agent against breast cancer for said patient by assaying a sample of breast cancer cells from said patient for the expression level(s) of one or more one genes in Table 2 or 3;
• and
• selecting the appropriate treatment for a patient with such a survival outcome.

A method to determine the survival outcome of a human subject having breast cancer if treated with tamoxifen or another antiestrogen agent against breast cancer, said method comprising assaying a sample of breast cells from said subject for expression of one or more human HOXB13, IL17BR or CACNA1D sequences or another sequence the expression of which is correlated with their expression in breast cancer cells,

• wherein underexpression of HOXB13 sequences is indicative of responsiveness, and overexpression of IL17BR and/or CACNA1D sequences is indicative of non-responsiveness, to treatment with tamoxifen or another antiestrogen agent against breast cancer.

A population of singled stranded nucleic acid molecules comprising one or both strands of a human IL17BR or CACNA1D or HOXB13 sequence wherein at least a portion of said population is hybridized to one or both strands of a nucleic acid molecule quantitatively amplified from RNA of a breast cell.

A method to determine the survival outcome of a human subject having breast cancer if treated with tamoxifen or another antiestrogen agent against breast cancer, said method comprising assaying a sample of breast cells from said subject for expression of a sequence selected from SEQ ID NOs:

• 8, 9, 11-17, or 32-34.

A method to determine the survival outcome of a human subject having breast cancer if treated with tamoxifen or another antiestrogen agent against breast cancer, said method comprising assaying a sample of breast cells from said subject for expression of a sequence selected from SEQ ID NOS:

• 10 18-31, or 35-37.

A method of predicting responsiveness or lack thereof in a breast cancer afflicted subject to treatment with tamoxifen or another o